Your browser doesn't support javascript.
loading
Engineered Cas9 extracellular vesicles as a novel gene editing tool.
Osteikoetxea, Xabier; Silva, Andreia; Lázaro-Ibáñez, Elisa; Salmond, Nikki; Shatnyeva, Olga; Stein, Josia; Schick, Jan; Wren, Stephen; Lindgren, Julia; Firth, Mike; Madsen, Alexandra; Mayr, Lorenz M; Overman, Ross; Davies, Rick; Dekker, Niek.
Affiliation
  • Osteikoetxea X; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Alderley Park, UK.
  • Silva A; HCEMM-SU Extracellular Vesicles Research Group, Budapest, Hungary.
  • Lázaro-Ibáñez E; Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary.
  • Salmond N; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Shatnyeva O; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Stein J; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Schick J; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Alderley Park, UK.
  • Wren S; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Lindgren J; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Alderley Park, UK.
  • Firth M; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Alderley Park, UK.
  • Madsen A; Global Product Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield, UK.
  • Mayr LM; Translational Genomics, Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Overman R; Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Davies R; Genome Engineering, Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Dekker N; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
J Extracell Vesicles ; 11(5): e12225, 2022 05.
Article in En | MEDLINE | ID: mdl-35585651
ABSTRACT
Extracellular vesicles (EVs) have shown promise as biological delivery vehicles, but therapeutic applications require efficient cargo loading. Here, we developed new methods for CRISPR/Cas9 loading into EVs through reversible heterodimerization of Cas9-fusions with EV sorting partners. Cas9-loaded EVs were collected from engineered Expi293F cells using standard methodology, characterized using nanoparticle tracking analysis, western blotting, and transmission electron microscopy and analysed for CRISPR/Cas9-mediated functional gene editing in a Cre-reporter cellular assay. Light-induced dimerization using Cryptochrome 2 combined with CD9 or a Myristoylation-Palmitoylation-Palmitoylation lipid modification resulted in efficient loading with approximately 25 Cas9 molecules per EV and high functional delivery with 51% gene editing of the Cre reporter cassette in HEK293 and 25% in HepG2 cells, respectively. This approach was also effective for targeting knock-down of the therapeutically relevant PCSK9 gene with 6% indel efficiency in HEK293. Cas9 transfer was detergent-sensitive and associated with the EV fractions after size exclusion chromatography, indicative of EV-mediated transfer. Considering the advantages of EVs over other delivery vectors we envision that this study will prove useful for a range of therapeutic applications, including CRISPR/Cas9 mediated genome editing.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Extracellular Vesicles / Gene Editing Limits: Humans Language: En Journal: J Extracell Vesicles Year: 2022 Document type: Article Affiliation country: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Extracellular Vesicles / Gene Editing Limits: Humans Language: En Journal: J Extracell Vesicles Year: 2022 Document type: Article Affiliation country: Reino Unido